Medexus Pharmaceuticals Receives Upgrade from Raymond James

On January 11, 2025, Raymond James made headlines by upgrading shares of Medexus Pharmaceuticals (TSE:MDP) from an outperform rating to a strong-buy rating. This update was detailed in a report released on Wednesday morning. The financial services firm has established a target price of C$4.00 for the stock, reflecting its confidence in the company’s potential.

In addition to the rating change, Raymond James provided its earnings estimates for Medexus Pharmaceuticals for several upcoming quarters. For Q3 2025, the estimate stands at ($0.03) earnings per share (EPS), followed by a forecast of ($0.06) EPS for Q4 2025. For the fiscal year 2025, they anticipate earnings of $0.03 EPS. Looking ahead, estimates for Q1 2026 are expected to reach $0.23 EPS, while Q3 and Q4 of 2026 are projected at $0.22 and $0.23 EPS, respectively. The overall earnings forecast for FY2026 is $0.89 EPS, which tapers slightly to $0.88 EPS and $0.80 EPS for FY2027 and FY2028, respectively. By FY2029, the company’s projected earnings stand at $0.77 EPS.

In a broader context, other analysts have also voiced their opinions on Medexus Pharmaceuticals. Notably, Alliance Global Partners upgraded the stock to a “strong-buy” rating just a few weeks earlier, on December 23, 2024. Furthermore, Leede Financial assigned a target price of C$8.25 to Medexus Pharmaceuticals, categorizing it as a “speculative buy.” Currently, two research analysts are recommending the stock with a buy rating, while four have assigned it a strong buy rating. According to MarketBeat.com data, the average rating for Medexus Pharmaceuticals is now categorized as “Strong Buy,” with a consensus price target of C$5.25.

Overview of Medexus Pharmaceuticals Performance

The stock of Medexus Pharmaceuticals showed positive movement as shares opened at C$4.04. The company holds a market capitalization of C$99.10 million, showcasing a P/E ratio of 80.80 alongside a beta of 1.96, indicating its volatility relative to the market. Over the last year, shares have traded within a 52-week range of C$1.47 to C$4.24. The stock’s 50-day and 200-day simple moving averages are C$2.77 and C$2.53, respectively, reflecting long-term trends.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company primarily in Canada and the United States. The company's focus areas include oncology, hematology, rheumatology, auto-immune diseases, allergies, and dermatology. Its product portfolio features IXINITY, an intravenous recombinant factor IX treatment for patients aged 12 years and older with hemophilia B, as well as Rasuvo and Metoject, which are formulations of methotrexate aimed at treating rheumatoid arthritis and other auto-immune conditions. Other significant products include Rupall, a prescription allergy medication, and Gleolan, an optical imaging agent used during surgery for patients with glioma to better visualize malignant tissue.

Medexus, Pharmaceuticals, Upgrade